We are live on ! Find out more
INDP icon

Indaptus Therapeutics
INDP

5 hedge funds and large institutions have $9.46M invested in Indaptus Therapeutics in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

213% more capital inflows, than outflows

Capital inflows: $2.49M | Capital outflows: $796K

3.16% more ownership

Funds ownership: 12.98% → 16.14% (+3.2%)

0% more funds holding

Funds holding: 5 → 5 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

Holders
5
Holders Change
–
Holders Change %
0%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Migdal Insurance & Financial Holdings
Migdal Insurance & Financial Holdings
Israel
+$2.47M
2
Deutsche Bank
Deutsche Bank
Germany
+$11.1K
3
Renaissance Technologies
Renaissance Technologies
New York
+$11.1K

Top Sellers

Rank Fund Capital Flow
1
NC
Nexthera Capital
New York
-$791K
2
UBS Group
UBS Group
Switzerland
-$5K

INDP Hedge Fund Activity: Q1 2017 in Review

5 of the 4,035 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q1 2017, worth a combined $9.46M — up 12% from $8.47M a quarter earlier.

Fund positioning in INDP was balanced in Q1 2017: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 0 trimmed.

The largest buyer was Migdal Insurance & Financial Holdings, opening a new position worth an estimated $2.47M. The largest seller was Nexthera Capital, exiting entirely with an estimated $791K sold.

  • 5 institutional investors held Indaptus Therapeutics (INDP) as of Q1 2017, unchanged from Q4 2016.
  • Funds reported $9.46M of Indaptus Therapeutics stock for Q1 2017, up 12% quarter-over-quarter.
  • 1 fund opened new Indaptus Therapeutics positions in Q1 2017 and 1 closed out, a net change of 0 holders.
  • The largest Indaptus Therapeutics buyer in Q1 2017 was Migdal Insurance & Financial Holdings, an estimated $2.47M added.
  • The largest Indaptus Therapeutics seller in Q1 2017 was Nexthera Capital, an estimated $791K sold.

Based on aggregated 13F filings for Q1 2017.